151 related articles for article (PubMed ID: 12684661)
1. Des-gamma-carboxy prothrombin in cancer and non-cancer liver tissue of patients with hepatocellular carcinoma.
Tang W; Miki K; Kokudo N; Sugawara Y; Imamura H; Minagawa M; Yuan LW; Ohnishi S; Makuuchi M
Int J Oncol; 2003 May; 22(5):969-75. PubMed ID: 12684661
[TBL] [Abstract][Full Text] [Related]
2. Clinical significance of simultaneous determinations of alpha-fetoprotein and des-gamma-carboxy prothrombin in monitoring recurrence in patients with hepatocellular carcinoma.
Aoyagi Y; Oguro M; Yanagi M; Mita Y; Suda T; Suzuki Y; Hata K; Ichii K; Asakura H
Cancer; 1996 May; 77(9):1781-6. PubMed ID: 8646674
[TBL] [Abstract][Full Text] [Related]
3. Serum des-gamma-carboxyprothrombin level by a modified enzyme immunoassay method in hepatocellular carcinoma: clinical significance in small hepatocellular carcinoma.
Soga K; Watanabe T; Aikawa K; Toshima M; Shibasaki K; Aoyagi Y
Hepatogastroenterology; 1998; 45(23):1737-41. PubMed ID: 9840138
[TBL] [Abstract][Full Text] [Related]
4. Usefulness of simultaneous determination of alpha-fetoprotein and des-gamma-carboxy prothrombin in hepatocellular carcinoma.
Nakao A; Taniguchi K; Inoue S; Harada A; Nonami T; Watanabe K; Takagi H
Semin Surg Oncol; 1996; 12(3):160-3. PubMed ID: 8727604
[TBL] [Abstract][Full Text] [Related]
5. Determination of serum des-gamma-carboxy prothrombin levels in patients with small-sized hepatocellular carcinoma: comparison of the conventional enzyme immunoassay and two modified methods.
Nomura F; Ishijima M; Horikoshi A; Nakai T; Ohnishi K
Am J Gastroenterol; 1996 Jul; 91(7):1380-3. PubMed ID: 8677999
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of abnormal prothrombin (DCP) in relation to postoperative survival and prognosis in patients with hepatocellular carcinoma.
Inoue S; Nakao A; Harada A; Nonami T; Takagi H
Am J Gastroenterol; 1994 Dec; 89(12):2222-6. PubMed ID: 7526679
[TBL] [Abstract][Full Text] [Related]
7. Clinical evaluation of plasma abnormal prothrombin (des-gamma-carboxy prothrombin) in hepatobiliary malignancies and other diseases.
Nakao A; Suzuki Y; Isshiki K; Kimura Y; Takeda S; Kishimoto W; Nonami T; Harada A; Takagi H
Am J Gastroenterol; 1991 Jan; 86(1):62-6. PubMed ID: 1702578
[TBL] [Abstract][Full Text] [Related]
8. [Clinical usefulness of plasma PIVKA-II assay and its limitations in patients with hepatocellular carcinoma].
Fujiyama S; Morishita T; Shibata J; Sato T
Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-1):1129-38. PubMed ID: 2471453
[TBL] [Abstract][Full Text] [Related]
9. Coagulation assays as diagnostic markers of hepatocellular carcinoma.
Lefrère JJ; Conard J; Mavier P; Bettan L; Beaugrand M; Gozin D; Lerable J; Dhumeaux D; Samama M
Thromb Haemost; 1988 Dec; 60(3):468-70. PubMed ID: 2467402
[TBL] [Abstract][Full Text] [Related]
10. [Clinical evaluation of PIVKA-II as a marker of hepatocellular carcinoma].
Arima K; Kodama T; Suga M; Sakamoto H; Ohe Y; Yachi A
Gan To Kagaku Ryoho; 1989 Aug; 16(8 Pt 2):3049-52. PubMed ID: 2476968
[TBL] [Abstract][Full Text] [Related]
11. Early detection of hepatocellular carcinoma associated with cirrhosis by combined assay of des-gamma-carboxy prothrombin and alpha-fetoprotein: a prospective study.
Izuno K; Fujiyama S; Yamasaki K; Sato M; Sato T
Hepatogastroenterology; 1995; 42(4):387-93. PubMed ID: 8586374
[TBL] [Abstract][Full Text] [Related]
12. Plasma abnormal prothrombin levels in patients with small hepatocellular carcinoma.
Tanabe Y; Ohnishi K; Nomura F; Iida S
Am J Gastroenterol; 1988 Dec; 83(12):1386-9. PubMed ID: 2461655
[TBL] [Abstract][Full Text] [Related]
13. Serum alpha-L-fucosidase activity and tumor size in hepatocellular carcinoma.
Takahashi H; Saibara T; Iwamura S; Tomita A; Maeda T; Onishi S; Yamamoto Y; Enzan H
Hepatology; 1994 Jun; 19(6):1414-7. PubMed ID: 7514563
[TBL] [Abstract][Full Text] [Related]
14. Clinical evaluation of plasma abnormal prothrombin (PIVKA-II) in patients with hepatocellular carcinoma.
Fujiyama S; Morishita T; Sagara K; Sato T; Motohara K; Matsuda I
Hepatogastroenterology; 1986 Oct; 33(5):201-5. PubMed ID: 2433199
[TBL] [Abstract][Full Text] [Related]
15. Hepatoid carcinoma of the lung with production of alpha-fetoprotein and abnormal prothrombin: an autopsy case report.
Nasu M; Soma T; Fukushima H; Kudo K; Matsubara O
Mod Pathol; 1997 Oct; 10(10):1054-8. PubMed ID: 9346187
[TBL] [Abstract][Full Text] [Related]
16. [Clinical usefulness of serum PIVKA-II levels determined by ECLIA system as a tumor maker for hepatocellular carcinoma].
Sakizono K; Oita T; Shibata Y; Tamura A; Kasakura S
Rinsho Byori; 1998 Sep; 46(9):936-41. PubMed ID: 9800480
[TBL] [Abstract][Full Text] [Related]
17. Acarboxy prothrombin (PIVKA II) as a tumour marker for hepatocellular carcinoma and other liver diseases.
Mohamedein A; Yousif-Kadaru AG; Ahmed SA; Saida H; Zaki ZA; Eldin ; Fedail SS
East Afr Med J; 1995 Sep; 72(9):584-7. PubMed ID: 7498046
[TBL] [Abstract][Full Text] [Related]
18. [Evaluation of plasma PIVKA-II as a new marker for hepatocellular carcinoma].
Tada H; Kagawa K; Hikita H; Takeuchi T; Ohta Y; Fukui S; Shintani H; Deguchi T; Okanoue T; Takino T
Gan No Rinsho; 1989 Apr; 35(5):564-70. PubMed ID: 2469809
[TBL] [Abstract][Full Text] [Related]
19. Abnormal prothrombin (DES-gamma-carboxy prothrombin) in hepatocellular carcinoma.
Nakao A; Virji A; Iwaki Y; Carr B; Iwatsuki S; Starzl E
Hepatogastroenterology; 1991 Oct; 38(5):450-3. PubMed ID: 1722483
[TBL] [Abstract][Full Text] [Related]
20. Des-gamma-carboxy prothrombin and proliferative activity of hepatocellular carcinoma.
Suehiro T; Matsumata T; Itasaka H; Taketomi A; Yamamoto K; Sugimachi K
Surgery; 1995 Jun; 117(6):682-91. PubMed ID: 7539944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]